Filing Flows › Health Care › Zomedica (ZOMDF)
Zomedica (ZOMDF) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Zomedica (ZOMDF) Q3 2026 earnings results →
Q3 2026 Revenue up 22% year over year to $9.9M · 32¢ of every $1 of revenue lost · operating margin -34.6%
Zomedica made $9.9M in Q3 2026 (+22% Y/Y): Consumables $6.8M, Capital $2.0M, Engineering $981K. Operating margin -34.6%, net loss $3.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.9M in Q3 2026, up 22% year over year and up 4% from the previous quarter. Consumables was the largest line at 69% of revenue. Consumables added $1.4M year over year (up 26%), 78% of the total change. Capital declined 9%.
Gross margin was 61.1%, down 6.1 points from Q3 2025. Operating costs exceeded revenue by $3.4M, an operating margin of -34.6%. Operating expenses fell 21% while revenue rose 22%. The quarter ended with a net loss of $3.2M, narrower than the previous quarter's $3.8M loss.
Operating cash flow was −$2.8M. Non-cash charges added back $1.8M of depreciation and amortization. Working capital and other items used $1.4M. Capital expenditures of $187K exceeded it, leaving free cash flow of −$3.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $9.9M | +22% | -34.6% | −$3.2M | −$2.8M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $9.5M | +37% | -42.9% | −$3.8M | −$2.6M |
| Q1 2026 | 10-Q | May 6, 2026 | $8.8M | +35% | -55.7% | −$4.5M | −$5.3M |
| Q4 2025 | 10-K | Mar 16, 2026 | $10.5M | +33% | -49.3% | −$4.5M | −$899K |
| Q3 2025 | 10-Q | Nov 4, 2025 | $8.1M | +16% | -81.6% | −$6.1M | −$4.7M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $7.0M | +14% | -115.4% | −$7.4M | −$5.4M |
| Q1 2025 | 10-Q | May 15, 2025 | $6.5M | +4% | -993.0% | −$63.8M | −$6.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Zomedica
Zomedica Corp. (“Zomedica” or the “Company”) was incorporated on January 7, 2013 under the Business Corporations Act (Alberta) as Wise Oakwood Ventures Inc. (“WOW”) and was classified as a capital pool company, as defined in Policy 2.4 of the TSX Venture Exchange. ZoMedica Pharmaceuticals Inc. (“ZoMedica”) was incorporated on May 14, 2015, under the Canada Business Corporations Act. On April 21, 2016, the Company closed its qualifying transaction (“Transaction”), consisting of the acquisition of ZoMedica pursuant to a three-cornered amalgamation, whereby ZoMedica was amalgamated with 9674128 Canada Inc. (which was wholly-owned by WOW) and common shares and options of the Company were issued to former holders of ZoMedica securities as consideration. The amalgamated company changed its name to Zomedica Pharmaceuticals Ltd.
In its own words, from its 10-K, filed Mar 16, 2026.
Zomedica against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +22% against the peers' median +10%. Operating margin: -34.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ZOMDF Zomedica | Q3 2026 | $9.9M | +22% | -34.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Zomedica 10-Q on SEC EDGAR · CIK 1684144 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns ZOMDF and who is buying
More on ZOMDF
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results